Alembic Limited. Q4 results show revenue rise from 33.05 to 39.15 crores, an 18.46% increase in growth. EPS also rise from ₹1.78 to ₹1.88, up by 5.62%.
First, Let’s Begin with Quarter-on-Quarter Basis:
Alembic Ltd. shared its Q4 results on Friday. They earned 39.15 crores in revenue this quarter, but that’s higher than the 33.05 crores they made last quarter. The company’s growth increased by 18.46 percent when comparing the two quarters.
In terms of profits, Alembic Ltd’s PAT (Profit After Tax) for this quarter was 48.25 crores, up from 45.62 crores in the previous quarter. Their quarter-to-quarter growth increased by 5.77 percent.
The company’s EPS (Earnings Per Share) this quarter is ₹1.88, which is an increase of 5.62% from the ₹1.78 EPS in the previous quarter.
Also read: ☞ ” Cipla Q4FY23 Results: Consolidated PAT Rises at Rs 525.65 Cr “
Now, Let’s Analyze the Results on a Year-over-Year Basis:
The company made a total revenue of 191.51 crores this year (2023), which is 14.40 percent higher than last year’s total revenue of 167.40 crores.
This year’s PAT (Profit After Tax) is 190.65 crores, which is also 14.14% higher than last year’s PAT of 222.06 crores.
The EPS (Earnings Per Share) for this year is ₹7.42, which is 14.22% more than the EPS of ₹8.65 earned last year.
The company earns the most revenue from its retail and telecom segments, which are its two major revenue sources.
Nimbark Share Dividend Announcement / Record Date:
The Board of Directors has declared a Final Dividend of ₹2.20 per Equity Share of Face Value of ₹2 each of the Company (110% of Face Value). Total Dividend for FY23 stood at ₹1.80 per Equity Share (Interim Dividend of ₹10 per Equity Share)
| Dividend | Record Date |
| ₹2.20 per Equity Share | Coming Soon |
The record date for the dividend has not arrived yet.
About Alembic:
Alembic Limited is a pharmaceutical company that operates through an integrated approach. Its product portfolio comprises various categories such as active pharmaceutical ingredients, bulk pharmaceuticals, domestic and international formulations, nutraceuticals and herbals, and veterinary products. The company is engaged in research across three main areas: chemistry and synthesis, formulations development, and contract research.
Download Full PDF Q4 Results of Alembic: Click Here
For more of the Latest News, Click Here
One thought on “Alembic Q4FY23 Results: Consolidated PAT Climbs at Rs 48.25 Cr”